HiFiBiO Therapeutics is aspiring to work on antibody therapies for different gastrointestinal diseases, cancers and other disorders by signing a pact with Japanese Pharma and biotech company Takeda.
Takeda CEO Christophe Weber aspires to make China its second most important market in the long run, accepting it as a major task in the future.
On Monday Takeda Pharmaceutical confirmed to acquire Shire for £45.3 billion ($61.50 billion). The final deal will be 46 percent cash and 54 percent stock.
New collaboration to explore the potential clinical benefits of two novel and complementary immuno-oncology mechanisms
Takeda has upped its offer to buy Shire $SHPG for a mix of stock and cash worth close to $65 billion, which is good enough for the Lexington, MA-based biotech to extend the deadline on their talks to May 8 after determining they were close to finalizing a pact.
Three of Takeda’s anticipated Shire buyout bids have already been rejected—and now, the Japanese drugmaker might just lose out to a competing bidder. Allergan, for instance, is already in talks for a buy.
Takeda is considering making a bold move for Shire, after announcing, as per UK regulations, that it may make an approach for the company.
First allogeneic stem cell therapy to receive central marketing authorization approval in Europe. Alofisel offers a new treatment option for patients who do not respond to current available therapies and may be subject to numerous invasive surgeries1
Takeda's inflammatory bowel disease treatment Entyvio has already been delivering blockbuster-plus sales, and the Japanese drugmaker sees fertile territory for more growth in the Asia-Pacific region.
Shares of Belgium-based TiGenix NV shot up more than 72 percent in pre-market trading after Japan’s Takeda Pharmaceuticals opted to acquire the company with which it has a developmental partnership for $630 million.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.